Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes

OncoImmunology

Volumn 5, Issue 5, 2016, Pages

  De Masson, A ^a,b,c   Giustiniani, J ^d,e   Marie Cardine, A ^a,b   Bouaziz, J D ^a,b   Dulphy, N ^a,b,f   Gossot, D ^g   Validire, P ^g   Tazi, A ^a,b   Garbar, C ^d,e   Bagot, M ^a,b   Merrouche, Y ^d,e   Bensussan, A ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d INSTITUT JEAN GODINOT   (France)

^e EA7319 ^*  (France)

^f INSERM   (France)

^g INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Cytotoxicity; Lymphocytes; NK cell receptor; NK cells

Indexed keywords

CD137 ANTIGEN; CD150 ANTIGEN; CD20 ANTIGEN; CD245 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GRANZYME B; INTERLEUKIN 2; MONOCLONAL ANTIBODY; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; P21 ACTIVATED KINASE 2; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; SURFACTANT PROTEIN A; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BIOTINYLATION; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DEGRANULATION ASSAY; EPSTEIN BARR VIRUS INFECTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NATURAL KILLER T CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

EID: 84965000124     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1127493     Document Type: Article

References (46)

1. E.B.Rosenberg, R.B.Herberman, P.H.Levine, R.H.Halterman, J.L.McCoy, J.R.Wunderlich. Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int J Cancer 1972; 9(3):648-58; PMID:4513057; http://dx.doi.org/10.1002/ijc.2910090323
2. D.M.Benson, M.A.Caligiuri. Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunol Res 2014; 2(2):99-104; PMID:24592397; http://dx.doi.org/10.1158/2326-6066.CIR-13-0219
3. A.Moffett-King. Natural killer cells and pregnancy. Nat Rev Immunol 2002; 2(9):656-63; PMID:12209134; http://dx.doi.org/10.1038/nri886
4. L.L.Lanier. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9(5):495-502; PMID:18425106; http://dx.doi.org/10.1038/ni1581
5. P.Le Bouteiller, A.Barakonyi, J.Giustiniani, F.Lenfant, A.Marie-Cardine, M.Aguerre-Girr, M.Rabot, I.Hilgert, F.Mami-Chouaib, J.Tabiasco et al. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc Natl Acad Sci U S A 2002; 99(26):16963-8; PMID:12486241; http://dx.doi.org/10.1073/pnas.012681099
6. A.Bensussan, E.Gluckman, S.E.MarsafyS el, V.Schiavon, I.G.Mansur, J.Dausset, L.Boumsell, E.Carosella. BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity. Proc Natl Acad Sci U S A 1994; 91(19):9136-40; PMID:8090781; http://dx.doi.org/10.1073/pnas.91.19.9136
7. I.Melero, J.V.Johnston, W.W.Shufford, R.S.Mittler, L.Chen. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190(2):167-72; PMID:9878117; http://dx.doi.org/10.1006/cimm.1998.1396
8. W.Lin, C.J.Voskens, X.Zhang, D.G.Schindler, A.Wood, E.Burch, Y.Wei, L.Chen, G.Tian, K.Tamada et al. Fc-dependent expression of CD137 on human NK cells: insights into «agonistic» effects of anti-CD137 monoclonal antibodies. Blood 2008; 112(3):699-707; PMID:18519814; http://dx.doi.org/10.1182/blood-2007-11-122465
9. H.E.Kohrt, A.D.Colevas, R.Houot, K.Weiskopf, M.J.Goldstein, P.Lund, A.Mueller, I.Sagiv-Barfi, A.Marabelle, R.Lira et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014; 124(6):2668-82; PMID:24837434; http://dx.doi.org/10.1172/JCI73014
10. H.E.Kohrt, R.Houot, K.Weiskopf, M.J.Goldstein, F.Scheeren, D.Czerwinski, A.D.Colevas, W.K.Weng, M.F.Clarke, R.W.Carlson et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122(3):1066-75; PMID:22326955; http://dx.doi.org/10.1172/JCI61226
11. H.E.Kohrt, R.Houot, M.J.Goldstein, K.Weiskopf, A.A.Alizadeh, J.Brody, A.Müller, R.Pachynski, D.Czerwinski, S.Coutre et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011; 117(8):2423-32; PMID:21193697; http://dx.doi.org/10.1182/blood-2010-08-301945
12. A.Marie-Cardine, L.Boumsell, A.Bensussan. The T-cell panel DY12 and DY35 mAbs define a novel receptor associated with protein tyrosine phosphatase activity in the leukeamic cell line YT indi. In: Leucocyte Typing VII. Oxford University Press. D.Mason; 2002, Oxford University press, New York, USA. Edition D Mason. p. 688.
13. J.Giustiniani, A.Marie-Cardine, A.Bensussan. A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity. J Immunol 2007; 178(3):1293-300; PMID:17237375; http://dx.doi.org/10.4049/jimmunol.178.3.1293
14. G.Dufresne-Martin, J.-F.Lemay, P.Lavigne, K.Klarskov. Peptide mass fingerprinting by matrix-assisted laser desorption ionization mass spectrometry of proteins detected by immunostaining on nitrocellulose. Proteomics 2005; 5(1):55-66; PMID:15602772; http://dx.doi.org/10.1002/pmic.200400902
15. I.-G.Mansur, V.Schiavon, J.Giustiniani, M.Bagot, A.Bensussan, A.Marie-Cardine. Engagement of IL-1 receptor accessory protein (IL-1RAcP) with the monoclonal antibody AY19 provides co-activating signals and prolongs the CD2-induced proliferation of peripheral blood lymphocytes. Immunol Lett 2011; 139(1–2):52-7; PMID:21600927; http://dx.doi.org/10.1016/j.imlet.2011.04.015
16. K.Mori, T.Furusawa, T.Okubo, T.Inoue, S.Ikawa, N.Yanai, K.J.Mori, M.Obinata. Genome structure and differential expression of two isoforms of a novel PDZ-containing myosin (MysPDZ) (Myo18A). J Biochem (Tokyo) 2003; 133(4):405-13; PMID:12761286; http://dx.doi.org/10.1093/jb/mvg053
17. C.-H.Yang, J.Szeliga, J.Jordan, S.Faske, Z.Sever-Chroneos, B.Dorsett, R.E.Christian, R.E.Settlage, J.Shabanowitz, D.F.Hunt et al. Identification of the surfactant protein A receptor 210 as the unconventional myosin 18A. J Biol Chem 2005; 280(41):34447-57; PMID:16087679; http://dx.doi.org/10.1074/jbc.M505229200
18. H.P.Haagsman, S.Hawgood, T.Sargeant, D.Buckley, R.T.White, K.Drickamer, B.J.Benson. The major lung surfactant protein, SP 28-36, is a calcium-dependent, carbohydrate-binding protein. J Biol Chem 1987; 262(29):13877-80; PMID:2820982
19. A.Mitsuhashi, H.Goto, T.Kuramoto, S.Tabata, S.Yukishige, S.Abe, M.Hanibuchi, S.Kakiuchi, A.Saijo, Y.Aono et al. Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages. Am J Pathol 2013; 182(5):1843-53; PMID:23499372; http://dx.doi.org/10.1016/j.ajpath.2013.01.030
20. A.Cerwenka, L.L.Lanier. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1(1):41-9; PMID:11905813; http://dx.doi.org/10.1038/35095564
21. T.B.McNeely, J.D.Coonrod. Aggregation and opsonization of type A but not type B Hemophilus influenzae by surfactant protein A. Am J Respir Cell Mol Biol 1994; 11(1):114-22; PMID:8018334; http://dx.doi.org/10.1165/ajrcmb.11.1.8018334
22. K.E.Pollok, Y.J.Kim, J.Hurtado, Z.Zhou, K.K.Kim, B.S.Kwon. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur J Immunol 1994; 24(2):367-74; PMID:8299685; http://dx.doi.org/10.1002/eji.1830240215
23. S.Zhao, H.Zhang, Y.Xing, Y.Natkunam. CD137 ligand is expressed in primary and secondary lymphoid follicles and in B-cell lymphomas: diagnostic and therapeutic implications. Am J Surg Pathol 2013; 37(2):250-8; PMID:23095505; http://dx.doi.org/10.1097/PAS.0b013e318268c6ea
24. D.M.Davis, I.Chiu, M.Fassett, G.B.Cohen, O.Mandelboim, J.L.Strominger. The human natural killer cell immune synapse. Proc Natl Acad Sci U S A 1999; 96(26):15062-7; PMID:10611338; http://dx.doi.org/10.1073/pnas.96.26.15062
25. G.D.Rak, E.M.Mace, P.P.Banerjee, T.Svitkina, J.S.Orange. Natural killer cell lytic granule secretion occurs through a pervasive actin network at the immune synapse. PLoS Biol 2011; 9(9):e1001151; PMID:21931536; http://dx.doi.org/10.1371/journal.pbio.1001151
26. A.C.N.Brown, S.Oddos, I.M.Dobbie, J.-M.Alakoskela, R.M.Parton, P.Eissmann, M.A.Neil, C.Dunsby, P.M.French, I.Davis et al. Remodelling of cortical actin where lytic granules dock at natural killer cell immune synapses revealed by super-resolution microscopy. PLoS Biol 2011; 9(9):e1001152; PMID:21931537; http://dx.doi.org/10.1371/journal.pbio.1001152
27. R.-M.Hsu, M.-H.Tsai, Y.-J.Hsieh, P.-C.Lyu, J.-S.Yu. Identification of MYO18A as a novel interacting partner of the PAK2/betaPIX/GIT1 complex and its potential function in modulating epithelial cell migration. Mol Biol Cell 2010; 21(2):287-301; PMID:19923322; http://dx.doi.org/10.1091/mbc.E09-03-0232
28. D.N.Burshtyn, A.M.Scharenberg, N.Wagtmann, S.Rajagopalan, K.Berrada, T.Yi, J.P.Kinet, E.O.Long. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 1996; 4(1):77-85; PMID:8574854; http://dx.doi.org/10.1016/S1074-7613(00)80300-3
29. C.C.Stebbins, C.Watzl, D.D.Billadeau, P.J.Leibson, D.N.Burshtyn, E.O.Long. Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol 2003; 23(17):6291-9; PMID:12917349; http://dx.doi.org/10.1128/MCB.23.17.6291-6299.2003
30. S.Mahmood, N.Kanwar, J.Tran, M.-L.Zhang, S.K.P.Kung. SHP-1 phosphatase is a critical regulator in preventing natural killer cell self-killing. PloS One 2012; 7(8):e44244; PMID:22952938; http://dx.doi.org/10.1371/journal.pone.0044244
31. A.K.Purdy, K.S.Campbell. SHP-2 expression negatively regulates NK cell function. J Immunol 2009; 183(11):7234-43; PMID:19915046; http://dx.doi.org/10.4049/jimmunol.0900088
32. H.C.Dippold, M.M.Ng, S.E.Farber-Katz, S.-K.Lee, M.L.Kerr, M.C.Peterman, R.Sim, P.A.Wiharto, K.A.Galbraith, S.Madhavarapu et al. GOLPH3 bridges phosphatidylinositol-4- phosphate and actomyosin to stretch and shape the Golgi to promote budding. Cell 2009; 139(2):337-51; PMID:19837035; http://dx.doi.org/10.1016/j.cell.2009.07.052
33. B.Samten, J.C.Townsend, Z.Sever-Chroneos, V.Pasquinelli, P.F.Barnes, Z.C.Chroneos. An antibody against the surfactant protein A (SP-A)-binding domain of the SP-A receptor inhibits T cell-mediated immune responses to Mycobacterium tuberculosis. J Leukoc Biol 2008; 84(1):115-23; PMID:18443188; http://dx.doi.org/10.1189/jlb.1207835
34. S.Mitra, C.Beach, G.-S.Feng, R.Plattner. SHP-2 is a novel target of Abl kinases during cell proliferation. J Cell Sci 2008; 121(20):3335-46; PMID:18827006; http://dx.doi.org/10.1242/jcs.035691
35. M.MacGillivray, M.T.Herrera-Abreu, C.-W.Chow, C.Shek, Q.Wang, E.Vachon, G.S.Feng, K.A.Siminovitch, C.A.McCulloch, G.P.Downey. The protein tyrosine phosphatase SHP-2 regulates interleukin-1-induced ERK activation in fibroblasts. J Biol Chem 2003; 278(29):27190-8; PMID:12721296; http://dx.doi.org/10.1074/jbc.M213083200
36. M.M.Andzelm, X.Chen, K.Krzewski, J.S.Orange, J.L.Strominger. Myosin IIA is required for cytolytic granule exocytosis in human NK cells. J Exp Med 2007; 204(10):2285-91; PMID:17875677; http://dx.doi.org/10.1084/jem.20071143
37. R.-M.Hsu, Y.-J.Hsieh, T.-H.Yang, Y.-C.Chiang, C.-Y.Kan, Y.-T.Lin, J.T.Chen, J.S.Yu. Binding of the extreme carboxyl-terminus of PAK-interacting exchange factor β (βPIX) to myosin 18A (MYO18A) is required for epithelial cell migration. Biochim Biophys Acta 2014; 1843(11):2513-27; PMID:25014165; http://dx.doi.org/10.1016/j.bbamcr.2014.06.023
38. T.Furusawa, S.Ikawa, N.Yanai, M.Obinata. Isolation of a novel PDZ-containing myosin from hematopoietic supportive bone marrow stromal cell lines. Biochem Biophys Res Commun 2000; 270(1):67-75; PMID:10733906; http://dx.doi.org/10.1006/bbrc.2000.2377
39. T.Nakano, M.Tani, M.Nishioka, T.Kohno, A.Otsuka, S.Ohwada, J.Yokota. Genetic and epigenetic alterations of the candidate tumor-suppressor gene MYO18B, on chromosome arm 22q, in colorectal cancer. Genes Chromosomes Cancer 2005; 43(2):162-71; PMID:15751041; http://dx.doi.org/10.1002/gcc.20180
40. M.Nishioka, T.Kohno, M.Tani, N.Yanaihara, Y.Tomizawa, A.Otsuka, S.Sasaki, K.Kobayashi, T.Niki, A.Maeshima et al. MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer. Proc Natl Acad Sci U S A 2002; 99(19):12269-74; PMID:12209013; http://dx.doi.org/10.1073/pnas.192445899
41. M.H.Taft, E.Behrmann, L.-C.Munske-Weidemann, C.Thiel, S.Raunser, D.J.Manstein. Functional characterization of human myosin-18A and its interaction with F-actin and GOLPH3. J Biol Chem 2013; 288(42):30029-41; PMID:23990465; http://dx.doi.org/10.1074/jbc.M113.497180
42. S.E.Farber-Katz, H.C.Dippold, M.D.Buschman, M.C.Peterman, M.Xing, C.J.Noakes, J.Tat, M.M.Ng, J.Rahajeng, D.M.Cowan et al. DNA damage triggers Golgi dispersal via DNA-PK and GOLPH3. Cell 2014; 156(3):413-27; PMID:24485452; http://dx.doi.org/10.1016/j.cell.2013.12.023
43. Y.Kuroki, S.Tsutahara, N.Shijubo, H.Takahashi, M.Shiratori, A.Hattori, Y.Honda, S.Abe, T.Akino. Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am Rev Respir Dis 1993; 147(3):723-9; PMID:8442609; http://dx.doi.org/10.1164/ajrccm/147.3.723
44. S.Rubio, T.Lacaze-Masmonteil, B.Chailley-Heu, A.Kahn, J.R.Bourbon, R.Ducroc. Pulmonary surfactant protein A (SP-A) is expressed by epithelial cells of small and large intestine. J Biol Chem 1995; 270(20):12162-9; PMID:7744866; http://dx.doi.org/10.1074/jbc.270.20.12162
45. H.A.S.Aiad, S.M.El-Farargy, M.M.Soliman, M.A.El-Wahed Gaber, S.A.El-Aziz Othman. Immunohistochemical staining of surfactant proteins A and B in skin of psoriatic patients before and after narrow-band UVB phototherapy. Am J Clin Dermatol 2012; 13(5):341-8; PMID:22621659; http://dx.doi.org/10.2165/11630720-000000000-00000
46. D.Cunningham, Y.Humblet, S.Siena, D.Khayat, H.Bleiberg, A.Santoro, D.Bets, M.Mueser, A.Harstrick, C.Verslype et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351(4):337-45; PMID:15269313; http://dx.doi.org/10.1056/NEJMoa033025